Tags

Type your tag names separated by a space and hit enter

Development of vaccines for SARS-CoV-2.
F1000Res. 2020; 9F

Abstract

COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches.

Links

PMC Free PDF

Authors+Show Affiliations

Ng WH
Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia.
Liu X
Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia.
Mahalingam S
Emerging Viruses, Inflammation and Therapeutics Group, Menzies Health Institute Queensland, Griffith University (Gold Coast Campus), Queensland, Australia.

MeSH

BetacoronavirusCOVID-19COVID-19 VaccinesChinaClinical Trials as TopicCoronavirus InfectionsHumansPandemicsPneumonia, ViralSARS-CoV-2Spike Glycoprotein, CoronavirusViral Vaccines

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32850116

Citation

Ng, Wern Hann, et al. "Development of Vaccines for SARS-CoV-2." F1000Research, vol. 9, 2020.
Ng WH, Liu X, Mahalingam S. Development of vaccines for SARS-CoV-2. F1000Res. 2020;9.
Ng, W. H., Liu, X., & Mahalingam, S. (2020). Development of vaccines for SARS-CoV-2. F1000Research, 9. https://doi.org/10.12688/f1000research.25998.1
Ng WH, Liu X, Mahalingam S. Development of Vaccines for SARS-CoV-2. F1000Res. 2020;9 PubMed PMID: 32850116.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development of vaccines for SARS-CoV-2. AU - Ng,Wern Hann, AU - Liu,Xiang, AU - Mahalingam,Suresh, Y1 - 2020/08/17/ PY - 2020/08/07/accepted PY - 2020/8/28/entrez PY - 2020/8/28/pubmed PY - 2020/9/2/medline KW - COVID-19 KW - SARS-CoV-2 KW - Vaccines JF - F1000Research JO - F1000Res VL - 9 N2 - COVID-19 emerged in late 2019 and has rapidly spread through many countries globally. The causative SARS-CoV-2 virus was not known until recently, and there is little or no natural immunity in human populations. There is an urgent need for vaccines and drugs to combat this new pandemic. In just a few months, huge efforts and resources by government, academia, and industry have been thrown into the race to develop a vaccine. This brief review summarizes and discusses the array of technologies being applied to vaccine development, highlighting the strengths and weaknesses of the various approaches. SN - 2046-1402 UR - https://www.unboundmedicine.com/medline/citation/32850116/Development_of_vaccines_for_SARS_CoV_2_ DB - PRIME DP - Unbound Medicine ER -